We report the case of a 66-year-old African American female with a history of breast cancer previously treated with anthracycline based chemotherapy presenting with significant mitral regurgitation. She initially had preserved left ventricular systolic function with normal cardiac chamber dimensions, however, she developed progressive left ventricular chamber dilation and mild reduction in systolic function, which prompted surgical correction of her mitral regurgitation. After surgical mitral valve repair, she developed overt left ventricular failure with severe systolic dysfunction; however, she responded well to subsequent medical therapy.
INTRODUCTION
Together, cardiovascular (CV) disease and cancer are responsible for nearly 48% of all deaths [1] . As efforts to combat these diseases continue to evolve, the prognosis of patients with CV disease and cancer has improved. Unfortunately, many anticancer treatments, such as anthracycline based chemotherapy regimens, pose significant threat to the heart. Published data suggests that more than 20% of patients treated with anthracycline exhibit evidence of left ventricular (LV) dysfunction late after chemotherapy, with approximately 5% developing overt heart failure [2] . Isolated mitral regurgitation (MR) after anthracycline exposure is not well characterized, although it develops in 10-15% of children with normal LV systolic function after anthracycline exposure [3, 4] . Furthermore, echocardiographic findings of MR may be an early predictor of anthracycline-induced cardiomyopathy [3] . We present the first case of an adult patient who developed significant MR with initially preserved left ventricular ejection fraction (LVEF) and normal cardiac chamber dimensions 5 years post anthracycline exposure.
CASE SUMMARY
A 66-year-old African American female was referred to our clinic for discomfort and fullness in her chest with arm tingling for 3 weeks duration with an abnormal electrocardiogram showing a non-specific T wave abnormality. She had been previously diagnosed with lymph node negative breast carcinoma in 6 years prior and received a left radical modified mastectomy addition to 6 cycles of 5-fluorouracil, cyclophosphamide, and doxorubicin; followed by adjuvant tamoxifen for 5 years. She had a history of gastroesophageal reflux disease, hyperlipidemia, and mild hypertension for 30 years prior, which was treated with atenolol. Subsequent transthoracic echocardiography (TTE) revealed normal LV wall thickness and chamber dimensions, LVEF of 57%, moderate MR, and normal right ventricular systolic pressure (RVSP, Table 1 ). Subsequent stress echocardiography was normal, showing no wall motion abnormalities. The patient was reassured given these benign findings.
A follow-up TTE 2 years later (7 years post-anthracycline) revealed normal LV chamber dimensions, LVEF of 50%, mild MR, and normal RVSP. A follow-up TTE 2 years later (9 years post--anthracycline) revealed moderate to severe MR, left atrial enlargement (LAE), and stable LV chamber size, systolic function, and RVSP (Table 1) . During the following 6 months, the patient developed orthopnea, exertional shortness of breath, and loss of stamina consistent with New York Heart Association class III congestive heart failure. Repeat TTE after the onset of these symptoms revealed LV chamber dilation (Table 1) Table 1 ).
The patient was instructed to continue valsartan and change atenolol to carvedilol. Follow-up TTE 4 months later revealed persistent LV systolic dysfunction with an LVEF of 20% (Table 1) , and spironolactone was added to her medical regimen.
Within the following year, she reported improvement in her shortness of breath and fatigue. A repeat BNP level was 38 pg/ mL. By 2 years post-mitral valve repair (12 years post-anthracycline) her LVEF improved to 45% on medical therapy (Table 1) .
At 3 years post-mitral valve repair (13 years post-anthracycline), her LV systolic function had normalized with an LVEF of 60% (Table 1) .
DISCUSSION
We reported the case of an adult patient presenting with signi- [5] . Regional subpapillary myocardial dysfunction may impair lateral shortening between the papillary muscles, which tethers the leaflet edges and impairs systolic leaflet closure, resulting in functional MR, even in the absence of LV and mitral annular dilation [6] . Therefore, functional MR may be a sign of subclinical anthracycline induced left ventricular dysfunction (i.e. abnormal myocardial contraction demonstrated by reduced LV strain despite normal LVEF). Indeed, MR occurs more often in children after anthracycline exposure compared to normal controls, and may herald the later development of overt anthracycline cardiomyopathy [3] .
Anthracycline induced cardiac toxicity also increases the sensitivity of the LV to loading conditions. In particular, increased afterload may precipitate LV systolic dysfunction after anthracycline exposure [7, 8] . In turn, patients with anthracycline exposure history often have abnormal myocardial contractile reserve in response to stress, which may identify higher risk for subsequent overt LV systolic dysfunction [9] . Significant MR causes a low resistance pathway for LV systolic ejection due to the relatively lower pressure in the left atrium compared to the aorta, which reduces overall LV afterload. Due to the removal of the low resistance regurgitant lesion with surgical correction, LV afterload can increase significantly after mitral valve repair or replacement [10] . This increase in LV afterload may precipitate cardiomyopathy with reduced LVEF [11, 12] , particularly in patients with poor contractile reserve such as those with anthracycline exposure history [13] . 
